clostridium%20difficile%20infection
CLOSTRIDIUM DIFFICILE INFECTION
Clostridium difficile infection is commonly associated with antibiotic treatment and is one of the most common nosocomial infections.
Symptoms usually start on days 4-9 of antibiotic treatment, but may also occur up to 8-10 weeks after discontinuation of antibiotics.
Discontinuation of antibiotics may be the only measure needed for patients with only mild diarrhea, no fever, no abdominal pain nor a high WBC count.
Cessation of antibiotics allows for reconstitution of the normal colonic microflora and markedly reduces risk of relapse.

Follow Up

Monitor Patient for Relapse

  • 20-25% of patients w/ C difficile infection will experience recurrent infection
    • Occurring <8 weeks after the onset of prior episode as long as symptoms of prior episode resolved after initial treatment was completed
  • Relapses are not usually due to development of antibiotic-resistant organisms
    • Usually due to germination of persistent spores in the colon after treatment or
    • Reinfection because of reingestion of the pathogen

Infection Control Measures

  • Proper handwashing between patient contacts must be observed
  • Isolate patients w/ C difficile-associated diarrhea
  • Use precautions when in contact w/ the infected patient & the environment
  • Objects & equipment must be properly disinfected
  • Educate patient & hospital staff regarding the disease
  • Judicious use of antibiotics must be exercised to prevent further cases of infection
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Use of potassium citrate and thiazides appears to improve health-related quality of life (HRQOL) among stone formers across all Wisconsin Stone Quality of Life (WISQOL) domains without increasing the likelihood of gastrointestinal complaints and fatigue or sexual complaints, respectively, reports a study.
Pearl Toh, 6 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
3 days ago
Eating high amounts of red and processed meat prior to a diagnosis of colorectal cancer appears to be associated with shorter survival time, although a possible weak association cannot be excluded, a study has shown.
3 days ago
Middle-aged Caucasian men who are dissatisfied with their marriage are at higher risk of sudden cardiac death regardless of other cardiovascular risk factors, a new study reports.